Cellular models to investigate biochemical pathways in Parkinson’s disease

Abstract

Cellular models are instrumental in dissecting a complex pathological process into simpler molecular events. Parkinson’s disease is multifactorial and clinically heterogeneous; the aetiology of the sporadic (and most common) form is still unclear and only a few molecular mechanisms have been clarified so far in the neurodegenerative cascade. In such a multifaceted picture, it is particularly important to identify experimental models that simplify the study of the different networks of proteins/genes involved. Cellular models that reproduce some of the features of the neurons that degenerate in Parkinson’s disease have contributed to many advances in our comprehension of the pathogenic flow of the disease. In particular, the pivotal biochemical pathways (i.e. apoptosis and oxidative stress, mitochondrial impairment and dysfunctional mitophagy, unfolded protein stress and improper removal of misfolded proteins) have been widely explored in cell lines, challenged with toxic insults or genetically modified. The central role of α‐synuclein has generated many models aiming to elucidate its contribution to the dysregulation of various cellular processes. In conclusion, classical cellular models appear to be the correct choice for preliminary studies on the molecular action of new drugs or potential toxins and for understanding the role of single genetic factors. Moreover, the availability of novel cellular systems, such as cybrids or induced pluripotent stem cells, offers the chance to exploit the advantages of an in vitro investigation, although mirroring more closely the cell population being affected.

Quercetin-mediated synthesis of graphene oxide–silver nanoparticle nanocomposites: a suitable alternative nanotherapy for neuroblastoma

“…6,10,12 Therefore, the selection of classical cellular models is critical to dissect the functional aspects and molecular mechanisms of action of new molecules, potential toxins, or cytotoxic agents. 13 Although highly advanced technologies are being developed for many types of cancers, including childhood oncological disorders, children with metastatic neuroblastoma have only a 5%-15% chance of long-term survival.…”

Cell-based assays for Parkinson's disease using differentiated human LUHMES cells

“…To identify neuroprotective agents for PD, cellular models are commonly used [7] . To establish such models, cell lines or primary neurons have been utilized with their own strength and weakness.…”

Current Screening Methodologies in Drug Discovery for Selected Human Diseases

“…Nowadays, the accumulated knowledge on the biological pathways involved in the neurodegeneration process shows that multiple neurodegenerative diseases have many features in common, including mitochondrial dysfunction, abnormalities in protein degradation pathways, axonal transport defects, and the ultimate induction of cell death pathways. This knowledge, together with the great advance on screening technologies, has contributed to develop phenotypic screenings with higher throughput in cellular, organotypic or small animal models (e.g., Caenorhabditis elegans , Drosophila , and zebrafish) [154,155]. These screens provide the opportunity to identify molecules that can modulate the biological pathways related to disease progression in ND.…”